July 25, 2016 12:35 AM ET


Company Overview of Open Monoclonal Technology, Inc.

Company Overview

Open Monoclonal Technology, Inc. operates as a biotechnology company. It offers OmniRat, an antibody platform that generates human monoclonal antibodies based on transgenic rats. Open Monoclonal Technology, Inc. has a strategic alliance with Crystal Bioscience, Inc. The company was founded in 2007 and is based in Palo Alto, California. As of January 8, 2016, Open Monoclonal Technology, Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

2747 Ross Road

Suite A

Palo Alto, CA 94303

United States

Founded in 2007





Key Executives for Open Monoclonal Technology, Inc.

Founder, Chief Executive Officer and Director
Chief Financial Officer
Chief Business Officer
Age: 53
Director of Research
Compensation as of Fiscal Year 2016.

Open Monoclonal Technology, Inc. Key Developments

Ligand Pharmaceuticals Incorporated, Open Monoclonal Technology, Inc. - M&A Call

To discuss the signing of agreements for Ligand to acquire OMT, Inc

Open Monoclonal Technology, Inc. Announces OmniAb(TM) License to Seattle Genetics

Open Monoclonal Technology, Inc. announced license that provides Seattle Genetics, Inc. with access to OMT's proprietary OmniRat(R), OmniMouse(R) and OmniFlic(TM) human antibody generation platforms. Seattle Genetics becomes OMT's nineteenth partner globally.

ARMO BioSciences, Inc. and Open Monoclonal Technology, Inc. Announce Licensing Agreement

ARMO BioSciences, Inc. (ARMO) and Open Monoclonal Technology, Inc. (OMT) announced a licensing agreement providing ARMO with exclusive rights to OMT’s Programmed Cell Death Protein 1 (PD-1) assets as well as unlimited access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic human antibody generation platforms. The addition of an anti-PD-1 program to ARMO's pipeline of cytokine immunotherapies reinforces the company's commitment to the development of safe and effective treatments for cancer. ARMO's clinical stage PEGylated form of recombinant human IL-10, known as AM0010, and anti-PD-1 antibodies work through complementary but distinct mechanisms on CD8+ T cells so the combination maximizes the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells, which are considered to be central to clinical response. In ongoing clinical studies, AM0010 has already shown activity as a monotherapy and in combination with anti-PD-1 agents in immune-sensitive tumors such as melanoma, RCC, NSCLC and others not previously thought to be sensitive to immunotherapy such as colorectal and pancreatic cancers. Early results from these trials are suggestive of AM0010's role in augmenting activated tumor infiltrating T cells and PD-1 expression, thereby bestowing anti-PD-1 sensitivity on tumors, including those that had been refractory to anti-PD-1 treatment.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

December 17, 2015

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Open Monoclonal Technology, Inc., please visit www.openmonoclonaltechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.